MSSP710: DECLINING STAGE-AT-DIAGNOSIS OF PANCREATIC ADENOCARCINOMA
Samuel W Hoppe, MD, Byron Faler, MD, FACS, Mangieri Christopher, MD; Eisenhower Army Medical Center
N.B. Please be advised that this research is ongoing; a final version of this abstract will be submitted to abstracts@sages.org by the previously defined deadline of 07 December 2018.
OBJECTIVES: Pancreatic adenocarcinoma carries a high mortality rate in part due to its late stage at diagnosis. Its indolent nature and vague presenting symptoms are thought to contribute to this phenomenon. However, with recent advances in cross-sectional imaging, these cancers are increasingly being identified incidentally. We postulated that, due to these increases in imaging resolution, we would expect to see an earlier stage-at-diagnosis in pancreatic adenocarcinoma.
METHODS: We queried the NSQIP database for cases of pancreatic cancer treated with pancreaticoduodenectomy between 2014 and 2016 and plotted stage-at-diagnosis. A total of 10,665 cases were compiled within NSQIP. This data was then compared to selected publications with comparable data identified in the PUBMED database.
RESULTS: We found that, as compared to historical data, current data on pancreatic cancer indicates that pancreatic adenocarcinoma is indeed being diagnosed at relatively earlier stages.
CONCLUSION: Pancreatic cancer is being diagnosed at relatively earlier stages relative to historic data. We postulate that this is due to advances in diagnostic abilities.